title: Concanavalin A-conjugated poly(ethylene glycol)-poly(lactic acid) nanoparticles for intranasal drug delivery to the cervical lymph nodes.
abstract: Concanavalin A (ConA)-conjugated poly(ethylene glycol)-poly(lactic acid) nanoparticles (ConA-NPs) were prepared for targeted drug delivery to the cervical lymph nodes after intranasal administration. ConA, a lectin specifically binding to α-mannose and α-glucose, was covalently conjugated on NPs without loss of its carbohydrates binding bioactivity. In vitro cellular uptake experiment demonstrated that NPs could be uptaken by Calu-3 cells in a time- and concentration-dependent manner, and conjugation of ConA on NPs could significantly increase the rate and amount of cellular uptake. ConA-NP showed no obvious toxicity to Calu-3 cells in vitro or to the nasal cilia of rats in vivo. Compared with NPs without ConA, ConA-NP is more effective in targeting drugs to the deep cervical lymph nodes, as evidenced by 1.36-2.52 times increase of targeting efficiency, demonstrating that ConA-NP is a potential carrier for targeted drug delivery to the cervical lymph nodes via nasal route.
authors: Department of Pharmaceutics, Key Laboratory of Smart Drug Delivery, School of Pharmacy, Fudan University; Ministry of Education and PLA , Shanghai 201203 , People's Republic of China.
authors: Xiayan
authors: X
authors: Shao
authors: Qingfeng
authors: Q
authors: Liu
authors: Chi
authors: C
authors: Zhang
authors: Xiaoyao
authors: X
authors: Zheng
authors: Jie
authors: J
authors: Chen
authors: Yuan
authors: Y
authors: Zha
authors: Yong
authors: Y
authors: Qian
authors: Xi
authors: X
authors: Zhang
authors: Qizhi
authors: Q
authors: Zhang
authors: Xinguo
authors: X
authors: Jiang
mesh_terms: D000281:Administration, Intranasal; D000818:Animals; D045744:Cell Line, Tumor; D002584:Cervix Uteri / Q000187:drug effects / Q000378:metabolism; D003208:Concanavalin A / Q000737:chemistry* / Q000378:metabolism / Q000633:toxicity; D003374:Coumarins / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics*; D004337:Drug Carriers / Q000737:chemistry* / Q000378:metabolism / Q000633:toxicity; D016503:Drug Delivery Systems; D005260:Female; D006801:Humans; D007773:Lactates / Q000737:chemistry* / Q000378:metabolism / Q000633:toxicity; D008198:Lymph Nodes / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D053758:Nanoparticles / Q000737:chemistry / Q000378:metabolism / Q000633:toxicity; D011092:Polyethylene Glycols / Q000737:chemistry* / Q000378:metabolism / Q000633:toxicity; D051381:Rats; D017207:Rats, Sprague-Dawley; D013844:Thiazoles / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics*
chemical_list: D003374:Coumarins; D004337:Drug Carriers; D007773:Lactates; D013844:Thiazoles; C517282:coumarin 6; C088513:poly(lactic acid-ethylene glycol); D003208:Concanavalin A; D011092:Polyethylene Glycols